Form 4: Cumberland Pharmaceuticals Director Caroline Young Acquires 1,000 Shares
SEC Form 4 Filing
Caroline Young, a director at Cumberland Pharmaceuticals, acquired 1,000 shares of common stock on March 17, 2025.
Summary
- On March 17, 2025, Caroline Young, a director of Cumberland Pharmaceuticals, acquired 1,000 shares of common stock at a price of $5.17 per share.
- This transaction increased her direct holdings to 32,318 shares.
- The acquisition was made through a restricted stock award that will vest 100% on March 17, 2026.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a stock acquisition by a director. While insider buying can be seen as positive, it's a small amount and doesn't necessarily indicate a major shift in the company's prospects.
Positives
- A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a director's investment in the company, which is common.
Stakeholder Impact
- The acquisition could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/17/2025 | Date of transaction: Caroline Young acquired 1,000 shares of common stock. |
| 03/17/2026 | Vesting date: Restricted stock award will vest 100%. |
| 03/18/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.